We measured quantitative dose responses for 53 breast cancer cell lines to inhibitors of PLK1, CENPE and AURKB/C designated GSK462364 GSK923295 and GSK1070916, respectively (Additional file 6). The gene discussed is PLK1; the disease is breast carcinoma.